MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy

Academic Article


  • The potential of α-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of α-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with α-particle emitters. Although α-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted α-particle emitter therapy and to provide guidance and recommendations for human α-particle emitter dosimetry. Copyright © 2010 by the Society of Nuclear Medicine, Inc.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Pubmed Id

  • 1883691
  • Author List

  • Sgouros G; Roeske JC; McDevitt MR; Palm S; Allen BJ; Fisher DR; Brill AB; Song H; Howell RW; Akabani G
  • Start Page

  • 311
  • End Page

  • 328
  • Volume

  • 51
  • Issue

  • 2